Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
A Phase 2, Open-label, Multi-centre, Multi-national Interventional Trial to Evaluate the Efficacy and Safety of Erdafitinib (ERDA) Monotherapy and Erdafitinib (ERDA) and Cetrelimab (CET) Combination as Neoadjuvant Treatment in Cisplatin-ineligible Patients With Muscle-invasive Bladder Cancer (MIBC) Whose Tumours Express Fibroblast Growth Factor Receptor ( FGFR ) Gene Alterations
Spanish Oncology Genito-Urinary Group
90 participants
Mar 7, 2023
INTERVENTIONAL
Conditions
Summary
Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.
Eligibility
Inclusion Criteria10
- Written informed consent stating that he or she understands the purpose of the study and the procedures involved and agrees to participate in the study.
- Histologically confirmed diagnosis of MIBC (Stage T2-4a N0/N1 M0) obtained via a diagnostic or maximal Transurethral Resection of Bladder Tumor (TURBT) performed no later than 3 months prior to start the screening visit.
- Pure or predominant (≥50%) urotelial Cancer (UC) histology as determined at the local site.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Decline or ineligible ("unfit") for cisplatin-based chemotherapy
- Presence of a selected FGFR alteration on analysis of tumour biopsy
- Adequate organ function
- No other malignancy
- Willingness to avoid pregnancy or fathering children
Exclusion Criteria5
- Clinical evidence of N2-N3 tumours or metastatic bladder cancer.
- Has tumour with any neuroendocrine or small cell component.
- Patients who are not considered fit for cystectomy or reject cystectomy.
- Prior FGFR-targeted or an immune checkpoint inhibitor (antiPD1/PDL1 )systemic therapy.
- Prior systemic therapy, radiation therapy, or surgery for bladder cancer
Interventions
Patients will receive treatment with erdafitinib alone (cohort 1)
Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06511648